One of the top stories in gastroenterology last week showed that Ibsrela reduced abdominal symptoms like bloating, cramping and fullness in patients with constipation-predominant irritable bowel syndrome.
A study that found Remicade (infliximab, Janssen) outperformed other ulcerative colitis treatments among biologic-naïve patients with moderate to severe active disease was another top story.
Ibsrela improves abdominal symptoms in IBS-C
Ibsrela (tenapanor, Ardelyx) helped reduce abdominal symptoms, like bloating, cramping and fullness, in patients with constipation-predominant irritable bowel syndrome, according to study results. Read more.
Infliximab is top among biologic-naive patients with UC
Infliximab ranked highest for induction of remission and endoscopic improvement among biologic-naive patients, according to a meta-analysis of treatments for moderately to severely active ulcerative colitis. Read more.
Weight loss may be an early clinical sign of early-onset CRC.
FDA clears endoscopy platform for use at ambulatory surgery centers
The FDA has given 510(k) clearance to the IMAGINA Endoscopy System, an endoscopy platform for gastrointestinal procedures at ambulatory surgery centers, according to a press release from the manufacturer, PENTAX Medical. Read more.
JAK inhibitors may increase risk for herpes zoster in patients with IBD
Patients with inflammatory bowel disease and other immune-mediated diseases who receive Janus kinase inhibitors may be at increased risk for herpes zoster infection, according to the results of a meta-analysis. Read more.
Weight loss may be an early clinical sign of early-onset CRC
Researchers from the University of California, San Diego, identified several factors, including increasing age and male sex, as potential risk factors for early-onset colorectal cancer, according to study results. Read more.